ClinicalTrials.gg
CompletedNCT01432938Updated Oct 7, 2014Results posted

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

A Phase 1 interventional study of dulaglutide and Warfarin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
49th of 54
28 · median 159
Started
2011
with 7 others
Phase 1
15 of 54
none open now
Registered
17th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 49th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 17th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Warfarin is a commonly used drug to prevent the blood from clotting. The purpose of this study is to determine if dulaglutide (LY2189265) affects how warfarin works. The study involves two different treatments (Treatment 1: warfarin; Treatment 2: dulaglutide + warfarin) separated by a minimum washout period of 24 days. In Treatment 1, the participant will receive 10 milligrams (mg) of warfarin on Day 1. In Treatment 2, the participant will receive a 1.5-mg dose of dulaglutide (LY2189265) as an injection on Day 1 and then a 10 mg dose of warfarin on Day 3. Participants will be randomly assigned into different treatment sequences. Participants in Treatment Sequence A will receive Treatment 1 then Treatment 2. Participants in Treatment Sequence B will receive Treatment 2 then Treatment 1.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male participants with female partners of , or partners who are pregnant or breastfeeding, agree to use a reliable method of from the time of the first dose until 3 months after the last dose of product, as determined by the investigator. The method may be one of the following:

    • condom with spermicidal agent
    • male participant sterilization
    • true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable)
  • female participants not of child-bearing potential and are or have undergone a documented hysterectomy (total or partial). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrolment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) with follicle stimulating hormone (FSH) ≥40 milli-international units per milliliter (mIU/mL)
  • have a (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2), inclusive, at screening
  • have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator
  • have venous access sufficient to allow for blood sampling
  • are reliable and willing to make themselves available for the duration of the study and are willing to follow study restrictions
  • have given written approved by Lilly and the ethical review board (ERB) governing the site

Exclusion criteria

Exclusion Criteria:

  • are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • have known allergies to glucagon-like-peptide 1 (GLP-1)-related compounds including dulaglutide or to warfarin, related compounds, or any components of either formulation
  • are persons who have previously completed or withdrawn from this study or any other study investigating dulaglutide in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening
  • history or presence of significant bleeding disorders that is, hematemesis, melena, severe or recurrent epistaxis, hemoptysis, hematuria, or intracranial hemorrhage
  • have a personal history, family history, or current evidence of a bleeding disorder, coagulopathy, or history of bleeding complications after surgical procedures, tooth extractions, nose or gingival bleeding, spontaneous bleeding (including bleeding into joint spaces)
  • have a personal or family history of polycystic kidney disease or protein C or S deficiency
  • have a history of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within the last 3 months prior to screening
  • have a history of or plan to undergo major surgery in the last 3 months prior to screening
  • show positive for a fecal occult blood test at screening
  • have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • have an abnormal blood pressure (after at least 5 minutes sitting) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • have a history or presence of cardiovascular, respiratory, hepatic, renal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (GE) (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs. Participants with mild dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician
  • Show evidence of significant active neuropsychiatric disease
  • have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  • regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • show evidence of (HIV) infection and/or positive human HIV antibodies
  • show evidence of and/or positive hepatitis C antibody
  • show evidence of and/or positive hepatitis B surface antigen
  • are women with a positive pregnancy test or women who are lactating
  • have used or intend to use over-the-counter medication other than acetaminophen within 7 days prior to the first dose of warfarin or dulaglutide or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy [HRT]) within 14 days prior to dosing. Aspirin and other nonsteroidal anti-inflammatory drugs should not be taken from 2 weeks prior to the first dosing occasion
  • show intended use of any drug or dietary supplement that may affect warfarin or coagulation within 14 days prior to the first dose of warfarin or dulaglutide or during the conduct of the study
  • use or intended use of a drug that inhibits or induces cytochrome P450 (CYP)1A2, CYP2C9, CYP2C19, or within 14 days prior to the first dose of warfarin or dulaglutide or during the conduct of the study
  • have donated blood of more than 500 milliliters (mL) within the month prior to screening
  • have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to stop alcohol consumption from 48 hours prior to admission (Day -1 of the first treatment period) until discharge (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • are smokers
  • have an /prothrombin time (INR/PT) or activated partial thromboplastin time (aPTT) above the normal reference range at screening
  • are females who menstruate
  • have consumed grapefruit, cranberries, or grapefruit- or cranberry-containing products within 7 days prior to the first dose of warfarin or dulaglutide
  • in the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
  • have any medical conditions, medical history or are taking any medication which are within the warfarin Product Information Leaflet
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Warfarin first, then Dulaglutide + Warfarin

    A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).

    Biological: dulaglutide · Drug: Warfarin

  • Experimental
    Dulaglutide + Warfarin first, then Warfarin

    A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).

    Biological: dulaglutide · Drug: Warfarin

Interventions

  • Biologicaldulaglutide

    Administered subcutaneously

    Also known as: LY2189265

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin

    Area under the concentration versus time curve (AUC) from zero to infinity was determined from plasma concentrations of the S- and R- enantiomers of warfarin.

    Time frame: Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)

  2. Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of R-warfarin and S-warfarin

    Time frame: Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)

  3. Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin

    Time frame: Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)

Secondary outcomes

  1. Pharmacodynamics: Area Under the International Normalized Ratio Curve (AUCINR) of Warfarin

    AUCINR was assessed from venous blood samples collected to determine the response variable INR at predose and at pre-determined intervals after the administration of warfarin.

    Time frame: Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)

  2. Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin

    Observed INRmax was assessed from venous blood samples collected to determine the response variable INR at predose and at pre-determined intervals after the administration of warfarin.

    Time frame: Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)

07

Results

Posted Oct 7, 2014

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneWarfarin First, Then Dulaglutide + WarfarinDulaglutide + Warfarin First, Then Warfarin
Started1414
Received at least 1 dose of study drug1414
Completed1214
Not completed20
Withdrew: Protocol violation10
Withdrew: Physician decision10
Washout Period of at Least 24 Days
Participant flow — Washout Period of at Least 24 Days
MilestoneWarfarin First, Then Dulaglutide + WarfarinDulaglutide + Warfarin First, Then Warfarin
Started1214
Completed1214
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneWarfarin First, Then Dulaglutide + WarfarinDulaglutide + Warfarin First, Then Warfarin
Started1214
Completed1114
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin

Area under the concentration versus time curve (AUC) from zero to infinity was determined from plasma concentrations of the S- and R- enantiomers of warfarin.

Time frame:
Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)
Reported as:
Geometric mean · nanograms times hours per milliliter
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of R-warfarin and S-warfarin
nanograms times hours per milliliterWarfarin AloneDulaglutide + Warfarin
S-warfarin19200 ± 2418900 ± 22
R-warfarin33000 ± 2532900 ± 24
PrimaryPharmacokinetics: Maximum Observed Drug Concentration (Cmax) of R-warfarin and S-warfarin
Time frame:
Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of R-warfarin and S-warfarin
nanograms per milliliter (ng/mL)Warfarin AloneDulaglutide + Warfarin
S-warfarin530 ± 19414 ± 23
R-warfarin530 ± 18451 ± 19
PrimaryPharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin
Time frame:
Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)
Reported as:
Median · hours
Pharmacokinetics: Time to Maximum Concentration (Tmax) of R-warfarin and S-warfarin
hoursWarfarin AloneDulaglutide + Warfarin
S-warfarin2.00 (1.00 to 4.00)4.00 (1.00 to 24.02)
R-warfarin2.00 (1.00 to 4.00)8.00 (2.00 to 24.02)
SecondaryPharmacodynamics: Area Under the International Normalized Ratio Curve (AUCINR) of Warfarin

AUCINR was assessed from venous blood samples collected to determine the response variable INR at predose and at pre-determined intervals after the administration of warfarin.

Time frame:
Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)
Reported as:
Geometric mean · ratio
Pharmacodynamics: Area Under the International Normalized Ratio Curve (AUCINR) of Warfarin
ratioWarfarin AloneDulaglutide + Warfarin
Pharmacodynamics: Area Under the International Normalized Ratio Curve (AUCINR) of Warfarin157 ± 5161 ± 5
SecondaryPharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin

Observed INRmax was assessed from venous blood samples collected to determine the response variable INR at predose and at pre-determined intervals after the administration of warfarin.

Time frame:
Predose (warfarin) and up to 144 hours postdose on Day 1 for Treatment 1 (warfarin alone) and on Day 3 for Treatment 2 (warfarin in combination with dulaglutide)
Reported as:
Geometric mean · ratio
Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin
ratioWarfarin AloneDulaglutide + Warfarin
Pharmacodynamics: Maximum Observed International Normalized Ratio (INRmax) of Warfarin1.24 ± 131.27 ± 15

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Warfarin Alone—0/28 (0%)3/28 (10.7%)
Dulaglutide Alone—0/26 (0%)5/26 (19.2%)
Dulaglutide + Warfarin—0/25 (0%)4/25 (16%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventWarfarin AloneDulaglutide AloneDulaglutide + Warfarin
VomitingGastrointestinal disorders0/283/260/25
DiarrhoeaGastrointestinal disorders1/280/262/25
NauseaGastrointestinal disorders0/282/261/25
Decreased appetiteMetabolism and nutrition disorders0/282/260/25
HeadacheNervous system disorders0/282/260/25
HaemorrhoidsGastrointestinal disorders0/280/261/25
Injection site painGeneral disorders0/280/261/25
Vision blurredEye disorders0/281/260/25
Abdominal painGastrointestinal disorders0/281/260/25
Gastrooesophageal reflux diseaseGastrointestinal disorders0/281/260/25

Baseline characteristics

Participants who received at least 1 dose of study drug (dulaglutide or warfarin).

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean44.2 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female4
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Entire Study Population
Hispanic or Latino7
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Entire Study Population
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American13
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
United States28
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75247, United States
09

References and documents

Publications

  • de la Pena A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017 Nov;56(11):1415-1427. doi: 10.1007/s40262-017-0531-7. PubMed 28357715 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2011
First posted
Sep 13, 2011
Start
Sep 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01432938
Responsible party
Sponsor
First posted
Sep 13, 2011
Start date
Sep 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion